SCHEMBL901637

SCHEMBL901637

CCC(C)NC(=O)c1cnn2c(O)c(Cc3ccccc3Cl)c(C)nc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 9/20 0.56
LMNA P02545 8/20 0.56
MAPT P10636 4/20 0.56
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 5/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 4/20 0.47
TSHR P16473 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
RUVBL1 Q9Y265 1/20 0.45
NPSR1 Q6W5P4 3/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5324086 0.86 HSD17B10 (0.61) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL901660 0.83 TP53 (0.64) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL902631 0.82 TP53 (0.72) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL902518 0.78 KDM4E (0.65) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL21159868 0.78 ALDH1A1 (0.66) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL15573367 0.77 LMNA (0.72) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL13413800 0.75 TP53 (0.51) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL901690 0.75 KDM4E (0.67) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL4794397 0.75 TP53 (0.72) TP53LMNAMAPTKDM4EALDH1A1
SCHEMBL15262396 0.74 HSD17B10 (0.66) TP53LMNAMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US claimed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP claimed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO claimed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
US-20100075993-A1 SMALL MOLECULE INHIBITORS AGAINST WEST NILE VIRUS REPLICATION DREXEL UNIVERSITY (US) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075993-A1 SMALL MOLECULE INHIBITORS AGAINST WEST NILE VIRUS REPLICATION MAVS, ZC3HAV1, KDM4E TP53 4425/4885LMNA 2265/4885MAPT 910/4885
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 TP53 2371/4885LMNA 4062/4885MAPT 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.